LRPPRC confers enhanced oxidative phosphorylation metabolism in triple-negative breast cancer and represents a

Qiqi Xue1,2,3, Wenxi Wang1,2, Jie Liu2

  • 1Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.

PubMed
Abstract

Insights

Triple-negative breast cancer (TNBC) relies on enhanced oxidative phosphorylation (OXPHOS). Targeting LRPPRC with gossypol acetate (GAA) inhibits OXPHOS and suppresses TNBC progression, offering a new therapeutic strategy.

Area of Science:

  • Molecular oncology
  • Metabolic pathways in cancer
  • Mitochondrial gene regulation

Background:

  • Triple-negative breast cancer (TNBC) is aggressive with unclear metabolic vulnerabilities.
  • Enhanced oxidative phosphorylation (OXPHOS) is a key metabolic feature of TNBC.
  • Current OXPHOS targeting strategies lack specificity.

Purpose of the Study:

  • To elucidate the molecular mechanism of enhanced OXPHOS in TNBC.
  • To identify novel therapeutic targets and strategies for TNBC.
  • To investigate the role of LRPPRC in TNBC progression and metabolism.

Main Methods:

  • Immunohistochemistry and sequencing data analysis to assess LRPPRC expression.
  • In vitro and in vivo assays to evaluate LRPPRC function in TNBC.
  • Seahorse XF assay to measure OXPHOS and energy metabolism.
  • Assessment of gossypol acetate (GAA) efficacy in LRPPRC suppression and OXPHOS inhibition.

Main Results:

  • LRPPRC is overexpressed in TNBC and promotes proliferation and metastasis.
  • LRPPRC upregulates mitochondrial gene expression, enhancing OXPHOS.
  • Gossypol acetate (GAA) binds LRPPRC, induces degradation, and inhibits OXPHOS.
  • GAA treatment suppressed TNBC cell proliferation, metastasis, and tumor formation in vivo.

Conclusions:

  • A novel pathway involving nuclear gene LRPPRC upregulating mitochondrial gene expression and OXPHOS in TNBC was identified.
  • LRPPRC is a promising therapeutic target for TNBC.
  • Gossypol acetate (GAA), a traditional gynecological drug, demonstrates significant antitumor activity against TNBC by targeting LRPPRC and OXPHOS.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
9.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K